ODD vs SKIN

For growth investors, Oddity Tech Ltd.

(ODD) is the stronger pick with 25. 2% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Oddity Tech Ltd. (ODD) offers the better valuation at 8. 3x trailing P/E (20. 2x forward), making it the more compelling value choice. Analysts rate Oddity Tech Ltd. (ODD) a "Hold" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Oddity Tech Ltd.

(ODD) delivered a total return of -68. 7%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: ODD returned -68. 7% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Oddity Tech Ltd.

(ODD) is the lower-risk stock at 0. 71β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 180% more volatile than ODD relative to the S&P 500. On balance sheet safety, Oddity Tech Ltd. (ODD) carries a lower debt/equity ratio of 10% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Oddity Tech Ltd.

(ODD) is pulling ahead at 25. 2% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to 8. 4% for Oddity Tech Ltd.. Over a 3-year CAGR, ODD leads at 35. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Oddity Tech Ltd.

(ODD) is the more profitable company, earning 13. 7% net margin versus -3. 2% for The Beauty Health Company — meaning it keeps 13. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ODD leads at 14. 7% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — ODD leads at 72. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ODD: 131.

7% to $34. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Oddity Tech Ltd.

(ODD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ODD: -68. 7%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ODD (Technology) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ODD is a small-cap high-growth stock; SKIN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.